Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials.
Blanter J, Van Hyfte G, Ahmad M, Xu S, Hapanowicz O, Fazilov G, Lu A, Lucas N, Wu K, Shelton G, DeMerchant M, Lachowicz M, Kier M, Werner M, Eder JP, Galsky MD, Marron TU, Smith CB, LoRusso PM, Hofstatter E, Doroshow DB. Blanter J, et al. Among authors: eder jp. JCO Oncol Pract. 2024 Dec 11:OP2400293. doi: 10.1200/OP.24.00293. Online ahead of print. JCO Oncol Pract. 2024. PMID: 39661920
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
Segal NH, Melero I, Moreno V, Steeghs N, Marabelle A, Rohrberg K, Rodriguez-Ruiz ME, Eder JP, Eng C, Manji GA, Waterkamp D, Leutgeb B, Bouseida S, Flinn N, Das Thakur M, Elze MC, Koeppen H, Jamois C, Martin-Facklam M, Lieu CH, Calvo E, Paz-Ares L, Tabernero J, Argilés G. Segal NH, et al. Among authors: eder jp. Nat Commun. 2024 May 15;15(1):4091. doi: 10.1038/s41467-024-48479-8. Nat Commun. 2024. PMID: 38750034 Free PMC article. Clinical Trial.
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.
Cecchini M, Walther Z, Wei W, Hafez N, Pilat MJ, Boerner SA, Durecki DE, Eder JP, Schalper KA, Chen AP, LoRusso P. Cecchini M, et al. Among authors: eder jp. Cancer Res Commun. 2023 Jun 26;3(6):1113-1117. doi: 10.1158/2767-9764.CRC-22-0485. eCollection 2023 Jun. Cancer Res Commun. 2023. PMID: 37377610 Free PMC article. Clinical Trial.
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop.
Clifton GT, Rothenberg M, Ascierto PA, Begley G, Cecchini M, Eder JP, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai SI, Provenzano P, Puré E, Ribas A, Schalper KA, Fridman WH. Clifton GT, et al. Among authors: eder jp. J Immunother Cancer. 2023 Jun;11(6):e006773. doi: 10.1136/jitc-2023-006773. J Immunother Cancer. 2023. PMID: 37290925 Free PMC article.
BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair.
Jimenez-Sainz J, Mathew J, Moore G, Lahiri S, Garbarino J, Eder JP, Rothenberg E, Jensen RB. Jimenez-Sainz J, et al. Among authors: eder jp. Elife. 2022 Sep 13;11:e79183. doi: 10.7554/eLife.79183. Elife. 2022. PMID: 36098506 Free PMC article.
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MP. Atrafi F, et al. Among authors: eder jp. Clin Cancer Res. 2022 Jul 1;28(13):2969. doi: 10.1158/1078-0432.CCR-22-1792. Clin Cancer Res. 2022. PMID: 35775194 No abstract available.
126 results